Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively 'Coeptis'), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have ... Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively 'Coeptis'), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Mehr anzeigen
Coeptis Therapeutics Announces Reverse Stock Split PR Newswire WEXFORD, Pa., Dec. 27, 2024 WEXFORD, Pa., Dec. 27, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the...
Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies PR Newswire WEXFORD, Pa., Dec. 26, 2024...
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies PR Newswire WEXFORD, Pa., Dec. 12, 2024 Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a...
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries PR Newswire WEXFORD, Pa., Dec. 3, 2024 The...
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development PR Newswire WEXFORD, Pa., Nov...
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use PR Newswire WEXFORD, Pa., Oct. 24, 2024 WEXFORD, Pa., Oct. 24, 2024 /PRNewswire/...
Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy PR Newswire WEXFORD, Pa., Oct. 15, 2024...
Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing PR Newswire WEXFORD, Pa., Sept. 19, 2024 WEXFORD, Pa., Sept. 19, 2024 /PRNewswire/...
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders PR Newswire WEXFORD, Pa., Sept. 5, 2024 WEXFORD, Pa., Sept. 5, 2024...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.18 | 70.0964630225 | 3.11 | 6.69 | 2.31 | 6742054 | 3.93551658 | CS |
| 4 | 1.37 | 34.9489795918 | 3.92 | 6.82 | 2.31 | 13533409 | 4.15335804 | CS |
| 12 | 1.69 | 46.9444444444 | 3.6 | 6.82 | 2.31 | 4476586 | 4.1581726 | CS |
| 26 | -0.21 | -3.81818181818 | 5.5 | 6.82 | 2.31 | 2146627 | 4.15408256 | CS |
| 52 | -10.31 | -66.0897435897 | 15.6 | 15.60202 | 2.31 | 1272296 | 4.61403636 | CS |
| 156 | -158.71 | -96.7743902439 | 164 | 175.102 | 2.31 | 677428 | 8.33758477 | CS |
| 260 | -158.71 | -96.7743902439 | 164 | 175.102 | 2.31 | 677428 | 8.33758477 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
